Exelixis, Inc.

LSE:0IJO Stock Report

Market Cap: US$9.7b

Exelixis Management

Management criteria checks 3/4

Exelixis' CEO is Mike Morrissey, appointed in Jul 2010, has a tenure of 14.42 years. total yearly compensation is $16.42M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth $29.34M. The average tenure of the management team and the board of directors is 8.6 years and 7.5 years respectively.

Key information

Mike Morrissey

Chief executive officer

US$16.4m

Total compensation

CEO salary percentage7.3%
CEO tenure14.4yrs
CEO ownership0.3%
Management average tenure8.6yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mike Morrissey's remuneration changed compared to Exelixis's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$467m

Jun 30 2024n/an/a

US$350m

Mar 31 2024n/an/a

US$205m

Dec 31 2023n/an/a

US$208m

Sep 30 2023n/an/a

US$92m

Jun 30 2023n/an/a

US$164m

Mar 31 2023n/an/a

US$154m

Dec 31 2022US$17mUS$1m

US$182m

Sep 30 2022n/an/a

US$308m

Jun 30 2022n/an/a

US$273m

Mar 31 2022n/an/a

US$298m

Dec 31 2021US$8mUS$1m

US$231m

Sep 30 2021n/an/a

US$164m

Jun 30 2021n/an/a

US$94m

Mar 31 2021n/an/a

US$65m

Dec 31 2020n/an/a

US$112m

Sep 30 2020n/an/a

US$152m

Jun 30 2020n/an/a

US$282m

Mar 31 2020n/an/a

US$294m

Dec 31 2019n/an/a

US$321m

Sep 30 2019n/an/a

US$612m

Jun 30 2019n/an/a

US$642m

Mar 31 2019n/an/a

US$650m

Dec 31 2018n/an/a

US$690m

Compensation vs Market: Mike's total compensation ($USD16.42M) is above average for companies of similar size in the UK market ($USD5.77M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.

CEO

Mike Morrissey (63 yo)

14.4yrs

Tenure

US$16,423,307

Compensation

Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...

Leadership Team

NamePositionTenureCompensationOwnership
Stelios Papadopoulos
Co-Founder & Chair of the Board30yrsUS$519.97k0.43%
$ 41.9m
Michael Morrissey
CEO, President & Director14.4yrsUS$16.42m0.30%
$ 29.3m
Christopher Senner
Executive VP & CFO9.4yrsUS$4.95m0.16%
$ 15.8m
Dana Aftab
Executive VP of Discovery and Translational Research & Chief Scientific Officer2yrsUS$5.65m0.080%
$ 7.7m
Jeffrey Hessekiel
Executive VP & General Counsel10.8yrsUS$4.56m0.093%
$ 9.0m
Amy Peterson
Executive VP1.3yrsUS$7.38m0.011%
$ 1.1m
Susan Hubbard
Executive Vice President of Public Affairs & Investor Relations8yrsno datano data
Tony Redmond
Senior Vice President of Human Resourcesless than a yearno datano data
Anne Champsaur
Senior Vice President of Drug Safety9.7yrsno datano data
William Berg
Senior Vice President of Medical Affairs9.3yrsno datano data
Patrick Haley
Executive Vice President of Commercial8yrsUS$4.65m0.036%
$ 3.5m
Stefan Krauss
VP & Head of Business Developmentno datano datano data

8.6yrs

Average Tenure

57yo

Average Age

Experienced Management: 0IJO's management team is seasoned and experienced (8.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stelios Papadopoulos
Co-Founder & Chair of the Board30yrsUS$519.97k0.43%
$ 41.9m
Michael Morrissey
CEO, President & Director14.4yrsUS$16.42m0.30%
$ 29.3m
Jack Wyszomierski
Independent Director20.8yrsUS$490.97k0.12%
$ 11.2m
George Poste
Independent Director20.3yrsUS$482.22k0.053%
$ 5.1m
Charles Sawyers
Member of the Scientific Advisory Boardno datano datano data
Ronald Evans
Member of the Scientific Advisory Boardno datano datano data
Sue Eckhardt
Independent Directorless than a yearno data0%
$ 0
Mary Beckerle
Independent Directorless than a yearno data0%
$ 0
Julie Smith
Independent Director8.3yrsUS$490.92k0.00027%
$ 26.1k
Maria Freire
Independent Director6.7yrsUS$488.72k0.025%
$ 2.4m
Robert Oliver
Independent Director1.6yrsUS$717.44k0.0016%
$ 153.5k
Tomas Heyman
Independent Director1.6yrsUS$716.19k0.0016%
$ 153.5k

7.5yrs

Average Tenure

68yo

Average Age

Experienced Board: 0IJO's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 08:41
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Exelixis, Inc. is covered by 40 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Peter LawsonBarclays
Etzer DaroutBMO Capital Markets Equity Research